首页> 外文期刊>Malaria Journal >Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania
【24h】

Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania

机译:使用含含磺酰胺的抗疟疾和蒿属素的成分的药物产生的不良药物事件:三个地区的发病率和家庭成本的调查结果在坦桑尼亚农村的常规人口监督系统

获取原文
           

摘要

Background Anti-malarial regimens containing sulphonamide or artemisinin ingredients are widely used in malaria-endemic countries. However, evidence of the incidence of adverse drug reactions (ADR) to these drugs is limited, especially in Africa, and there is a complete absence of information on the economic burden such ADR place on patients. This study aimed to document ADR incidence and associated household costs in three high malaria transmission districts in rural Tanzania covered by demographic surveillance systems. Methods Active and passive surveillance methods were used to identify ADR from sulphadoxine-pyrimethamine (SP) and artemisinin (AS) use. ADR were identified by trained clinicians at health facilities (passive surveillance) and through cross-sectional household surveys (active surveillance). Potential cases were followed up at home, where a complete history and physical examination was undertaken, and household cost data collected. Patients were classified as having ‘possible’ or ‘probable’ ADR by a physician. Results A total of 95 suspected ADR were identified during a two-year period, of which 79 were traced, and 67 reported use of SP and/or AS prior to ADR onset. Thirty-four cases were classified as ‘probable’ and 33 as ‘possible’ ADRs. Most (53) cases were associated with SP monotherapy, 13 with the AS/SP combination (available in one of the two areas only), and one with AS monotherapy. Annual ADR incidence per 100,000 exposures was estimated based on ‘probable’ ADR only at 5.6 for AS/SP in combination, and 25.0 and 11.6 for SP monotherapy. Median ADR treatment costs per episode ranged from US$2.23 for those making a single provider visit to US$146.93 for patients with four visits. Seventy-three per cent of patients used out-of-pocket funds or sold part of their farm harvests to pay for treatment, and 19% borrowed money. Conclusion Both passive and active surveillance methods proved feasible methods for anti-malarial ADR surveillance, with active surveillance being an important complement to facility-based surveillance, given the widespread practice of self-medication. Household costs associated with ADR treatment were high and potentially catastrophic. Efforts should be made to both improve pharmacovigilance across Africa and to identify strategies to reduce the economic burden endured by households suffering from ADR.
机译:背景技术含磺酰胺或青蒿素成分的抗疟疾方案广泛用于疟疾流行国家。然而,对这些药物的不良药物反应(ADR)发病率的证据是有限的,特别是在非洲,并完全没有关于患者患者的经济负担的信息。本研究旨在记录坦桑尼亚农村三个高疟疾传输区的ADR发病率和相关的家庭成本。方法使用活性和无源监测方法鉴定亚磺酰胺 - 吡米甲胺(SP)和氨化蛋白(AS)使用的ADR。 ADR通过培训的临床医生在卫生设施(被动监测)和横断面家庭调查(积极监控)上进行识别。潜在的案件在家里随访,正在进行完整的历史和体检,并收集家庭成本数据。患者被医生分类为“可能”或“可能”的ADR。结果在两年期间鉴定了95个疑似ADR,其中79例追踪,67例报告使用SP和/或ADR发作前的使用。三十四个案件被归类为“可能”和33作为“可能”ADRS。大多数(53)案例与SP单药疗法有关,13个用AS / SP组合(仅在两个区域中的一个),以及作为单一疗法的单药。每100,000个暴露的年度ADR发病率仅基于“可能”ADR,仅适用于AS / SP的5.6,以及SP单药治疗的25.0和11.6。对于患有四次访问的患者,每次集中的中位数ADR治疗费用为2.23美元的价格为146.93美元。百分之七十三名患者患者使用外包资金或出售他们的部分农场收获来支付治疗费用,而且借入了19%的钱。结论鉴于自我用药的广泛实践,鉴于自我用药的广泛实践,鉴于自我用药的广泛实践,证明了防疟疾ADR监测的可行方法是对基于设施的监测的重要补充。与ADR治疗相关的家庭成本高,潜在的灾难性。应努力改善非洲的药物文化,并确定减少患有ADR遭受的家庭经济负担的策略。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号